http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102144999-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a843c3bc6ef616d46ada26b7194ec53
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
filingDate 2010-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2013-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc4fd4b959b9621b2532c92f9bb6b01c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b904206ae739917feb826ac519bb2ee3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dedeb04d6fdeae2ad9f30c07dacb1472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2eb50919ae1dc5966d5a4facb63367a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03371dc3094262dd20e6e8c9b98aa935
publicationDate 2013-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102144999-B
titleOfInvention Application of senkyunolide H in preparing medicine for preventing and curing cerebral apoplexy
abstract The invention discloses a novel pharmaceutical application of senkyunolide H (represented by formula I). The invention adopts an animal model to study the influence of the senkyunolide H on the cerebral blood flow change in an MCAO (middle cerebral artery occlusion)-caused local cerebral ischemia reperfusion rat model and a KCl (potassium chloride)-induced cortical spreading depression rat model. Pharmacological results prove that senkyunolide H can remarkably increase the cerebral blood flow of a rat after MCAO modeling, and rapidly restore or even exceed the original cerebral blood flow before modeling after filling is performed, and show a certain brain protection effect. In addition, senkyunolide H can resist the cerebral blood flow decrease caused by KCl-induced rat local cerebral vasoconstriction, Therefore, senkyunolide H can be used for preparing a medicine for preventing and curing cerebral apoplexy.
priorityDate 2010-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5321251
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448981304
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426072836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2707
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491273
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID40916
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22242641
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21584188
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453706507
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID49555
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453569306
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID40916
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419528628
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID61361
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4873
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID49555

Total number of triples: 32.